RVMD Share Price Performance
US$101.19
61.57 (155.40%)
40.5% undervalued intrinsic discount
US$170.00
Fair Value
Price US$101.19
AnalystHighTarget US$170.00
Fair ValueUS$170.00
Share Pricen/a
Revolution Medicines, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
RVMD Community Narratives
AN
Fair Value US$170 40.5% undervalued intrinsic discount
RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity
Catalysts About Revolution Medicines Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations, with a broad portfolio of RAS(ON) inhibitors across multiple tumor types. What are the underlying business or industry changes driving this perspective?Read more
0
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$170
40.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Profit Margin
20.03%
Future PE
117.44x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity
Fair Value: US$170 40.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Revolution Medicines, Inc. Key Details
About RVMD
- Founded
- 2014
- Employees
- 883
- CEO
- WebsiteView website
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). The company has commercialization agreement with Aventis, Inc. to research and develop SHP2 inhibitors, including RMC-4630, for indications.Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
